BMY Q2 Earnings: 58% Growth, Priced In

Bristol Myers Squibb just reported the quarter that proves the patent cliff transition is real. The question is whether you can still make money on it.

BMY closed at $63.10 on July 29, giving the company a market cap of $128.9 billion. That prices in a lot of good news. Here is what the Q2 2026 numbers actually tell us, and where the value is and is not.

The Quarter: Growth Portfolio Hits 58%

Q2 2026 revenue came in at $13.0 billion, up 6% year over year. Non-GAAP EPS was $2.04, a 40% jump from $1.46 in Q2 2025. BMY raised full-year revenue guidance from $46.0 to $47.5 billion up to $49.0 to $50.0 billion, and lifted EPS guidance from $6.05 to $6.35 up to $6.75 to $7.00.

The Growth Portfolio, which BMY defines as products early in their lifecycle, generated $7.6 billion in revenue, up 15% (14% ex-FX). That is now 58% of total revenue. The Legacy Portfolio fell 4% to $5.4 billion, dragged by Revlimid (down 49% to $425 million WW) and Pomalyst (down 71% to $204 million WW). The generic erosion of the Celgene-era myeloma franchise is playing out exactly as expected.

The standout growers: Reblozyl at $735 million WW (+29% YoY), Camzyos at $416 million WW (+60%), and Breyanzi at $484 million WW (+41%). Opdivo Qvantig, the subcutaneous formulation, added $261 million WW in its first full year. Even Eliquis held strong at $4.48 billion WW (+22%), though its U.S. patent cliff hits in 2028.

The transition from Legacy to Growth is not a narrative. It is happening in the numbers. The question is whether $129 billion already reflects it.

The Reblozyl Myelofibrosis Filing: A Bet on Secondary Endpoints

The most interesting pipeline announcement from Q2 was the FDA accepting the Reblozyl sBLA for myelofibrosis-associated anemia, with a PDUFA date of March 11, 2027. Reblozyl is already approved in MDS and beta-thalassemia, so this is a label expansion into a new indication.

Here is the catch: the Phase 3 INDEPENDENCE trial (NCT04717414) missed its primary endpoint. The trial evaluated Reblozyl plus a JAK inhibitor versus placebo in transfusion-dependent myelofibrosis patients. The primary endpoint was RBC transfusion independence for any consecutive 12-week period within the first 24 weeks. It missed with p=0.0674, according to BMS’s July 2025 press release.

BMY is filing anyway, leaning on secondary endpoints: a higher proportion of patients achieving at least 50% reduction in RBC transfusion burden, and more patients achieving a hemoglobin increase of 1 g/dL or more while transfusion independent for 12 weeks. These are clinically meaningful but they are not the endpoint the trial was powered for. Filing an sBLA on a missed primary endpoint is a calculated regulatory bet. The FDA could approve on secondary data, issue a Complete Response Letter, or request additional data. The filing is 50/50 at best, and the market is not pricing any Reblozyl MF revenue into the stock yet.

Reblozyl at $735 million Q2 revenue growing 29% is already a strong franchise without the MF label. If the sBLA succeeds, the addressable population expands. If it fails, the core MDS and beta-thalassemia business still compounds. The MF filing is option value, not a thesis.

The CELMoD Pipeline: Two PDUFAs, One Mechanism, All the Marbles

The real pipeline story is the CELMoD platform. BMY has two cereblon E3 ligase modulators under FDA review for relapsed or refractory multiple myeloma, and both could be approved within 12 months.

Iberdomide has a PDUFA date of August 17, 2026, based on the Phase 3 EXCALIBER-RRMM trial (NCT04975997). The trial evaluated iberdomide plus daratumumab and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in RRMM patients. The FDA granted Breakthrough Therapy designation and Priority Review. The filing is supported by MRD negativity data from a planned interim analysis. The dual primary endpoints are MRD negativity and PFS. Iberdomide degrades Ikaros and Aiolos transcription factors, inhibiting myeloma cell growth and stimulating immunity.

Mezigdomide has a PDUFA date of May 13, 2027, based on the Phase 3 SUCCESSOR-2 trial. The data is stronger here: mezigdomide plus carfilzomib and dexamethasone (MeziKd) achieved median PFS of 18.0 months versus 8.3 months for carfilzomib and dexamethasone alone (Kd). The hazard ratio was 0.48 (95% CI 0.36 to 0.63, p<0.0001), representing a 52% reduction in risk of disease progression or death. This is a clinically meaningful PFS benefit in a heavily pretreated population where 86% were refractory to anti-CD38 antibodies and 76% were refractory to lenalidomide. We previously analyzed the mezigdomide PDUFA when the NDA was accepted.

Two CELMoDs for the same indication from the same company is unusual. The competitive picture in myeloma is crowded: Sanofi’s sarilisa with an on-body injector is pushing into earlier lines, and Gilead’s anito-cel BCMA CAR-T PDUFA is targeting the BCMA CAR-T space. BMY is betting that oral CELMoDs can compete with infused CAR-T on convenience and cost. The PFS data from SUCCESSOR-2 supports that bet for now.

Cobenfy: The Schizophrenia Launch Is Slow

Cobenfy, BMY’s first-in-class muscarinic agonist for schizophrenia, generated $63 million WW in Q2, up 81% YoY. That sounds impressive until you see the base: $35 million in Q2 2025. Full-year 2025 revenue was $155 million. For a drug that analysts once projected could reach $5 billion at peak, this is a slow ramp.

The launch challenges are real: payer prior authorization hurdles, physician unfamiliarity with a novel mechanism, and titration complexity. The schizophrenia space is also seeing new entrants, including MapLight’s ML-007 schizophrenia Phase 2 data, though that program is still in Phase 2. Cobenfy’s Alzheimer’s psychosis readout (ADEPT trial) could expand the franchise, but that data is not due until later in 2026.

At $63 million per quarter, Cobenfy is tracking to roughly $300 million in 2026. That is 0.6% of BMY’s guided $49.5 billion revenue. The drug is immaterial to the stock at current trajectory, though the option value on expanded indications is real.

Valuation: Priced for Execution, Not Surprise

BMY at $128.9 billion market cap trades at approximately 2.6x its updated 2026 revenue guidance midpoint of $49.5 billion. Compare that to Gilead (GILD) at $164.8 billion, which trades at 3.2x its revenue base. Merck (MRK) at $322 billion trades at roughly 3.4x revenue. BMY’s discount reflects the patent cliff overhang: Eliquis loses U.S. exclusivity in 2028, and Opdivo faces biosimilar competition in the late 2020s.

The Growth Portfolio’s 15% growth rate is real, but BMY’s P/S multiple of 2.6x is already in line with a mid-cycle pharma working through a patent cliff. There is no compression multiple to expand from. For comparison, GILD trades at a premium because its HIV franchise has longer patent protection and its oncology pipeline (Trodelvy, anito-cel) has clearer $1B+ revenue potential.

The non-GAAP EPS guidance of $6.75 to $7.00 puts BMY at a forward P/E of roughly 9x at $63.10. That is cheap relative to large-cap pharma peers, but it should be: the 2028 Eliquis cliff and the Opdivo biosimilar wave are structural headwinds that compress the multiple.

Risks

The biggest risk is the iberdomide PDUFA on August 17. If the FDA approves, the stock gets a modest bump. If the FDA issues a CRL, particularly given that the EXCALIBER-RRMM trial used MRD negativity as a primary endpoint, which the FDA has historically resisted as a sole approval basis, the stock loses 5 to 10% on re-rating of the CELMoD pipeline. MRD negativity is a surrogate endpoint, and the FDA’s willingness to approve on it alone is not guaranteed despite the Breakthrough Therapy designation.

The Reblozyl MF sBLA carries the same risk at lower stakes. Filing on a missed primary endpoint (p=0.0674) is a regulatory gamble. A CRL in March 2027 would not dent the core Reblozyl franchise but would signal that BMY’s regulatory strategy is more aggressive than the FDA is comfortable with.

The 2028 Eliquis patent cliff is the structural ceiling on the multiple. Eliquis generated $4.48 billion WW in Q2 alone, making it BMY’s largest product. Generic apixaban in 2028 will erase billions in annual revenue, and no pipeline asset currently in late-stage development can replace that scale.

Verdict: Hold at $63

BMY is executing the patent cliff transition as well as any big pharma could. The Growth Portfolio at 58% of revenue and growing 15% is the proof. The guidance raise to $49.5 billion midpoint is credible. But at $128.9 billion, the market is already paying for this execution.

The catalysts are real but the stock-moving ones are binary: iberdomide on August 17 and mezigdomide in May 2027. Between now and then, BMY is a 9x earnings stock with a 2028 cliff and a slow Cobenfy launch. Do not short it, but do not add here either. The right entry is after the iberdomide PDUFA, when you know whether the CELMoD thesis holds. If iberdomide is approved, BMY is a Hold with modest upside to the mid-$70s on pipeline re-rating. If it gets a CRL, sub-$60 is in play.

For biotech investors looking for a myeloma pure play, BMY is the wrong vehicle. The CELMoD pipeline is one piece of a $129 billion puzzle. The real question for BMY is not whether the Growth Portfolio works. It does. The question is whether the market will ever pay more than 2.6x sales for a company with a 2028 cliff. At current prices, the answer is: not yet.